InSynchrony Ventures is a new breed of biotech investor that strongly believes in the concept of "smart money". We’ve combined InSynchrony’s capital with the proven expertise of InSymbiosis (a collaborative drug development company that was previously established by one of the founders of InSynchrony) to deliver a unique investment formulation. Furthermore, we focus on the earlier phases of development where most of the funding challenges exist. We believe that providing the capital and expertise at this crucial moment is key to allowing new inventions and technologies to show their true potential.
InSynchrony Ventures’ interests and expertise lie in early stage therapeutics development. Therefore, from an investment perspective, we are most interested in therapeutic companies whose programs are between preclinical and early clinical stages. We are therapeutically agnostic and typically require that the company has the following profile:
To begin the discussion, please submit a non-confidential presentation and/or executive summary for review.
We recently announced the closing of Atriva’s series A financing which was needed to support the first-in-humans study.…
Since its founding in 2015 by a leading team of viral research scientists in Germany, Atriva has progressed…
According to the CDC, “antibiotic resistance is one of the most urgent threats to the public’s health”. Antibiotic…
Colorado-based Cetya Therapeutics (“Cetya”) is part of InSynchrony Ventures’ investment portfolio and we are excited to share that…
We announced our participation in the seed financing of Atriva Therapeutics back in July and are delighted to…
Copyright © 2019 InSynchrony Ventures. All rights reserved. Creation by Netfolie.com